CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model.

MLA

Campagne, Olivia, et al. “CNS Penetration and Pharmacodynamics of the CHK1 Inhibitor Prexasertib in a Mouse Group 3 Medulloblastoma Model.” European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, vol. 142, Jan. 2020, p. 105106. EBSCOhost, https://doi.org/10.1016/j.ejps.2019.105106.

APA

Campagne, O., Davis, A., Maharaj, A. R., Zhong, B., Stripay, J., Farmer, D., Roussel, M. F., & Stewart, C. F. (2020). CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 142, 105106. https://doi.org/10.1016/j.ejps.2019.105106

Chicago

Campagne, Olivia, Abigail Davis, Anil R Maharaj, Bo Zhong, Jennifer Stripay, Dana Farmer, Martine F Roussel, and Clinton F Stewart. 2020. “CNS Penetration and Pharmacodynamics of the CHK1 Inhibitor Prexasertib in a Mouse Group 3 Medulloblastoma Model.” European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences 142 (January): 105106. doi:10.1016/j.ejps.2019.105106.